Seres Therapeutics Inc
MCRB
Company Profile
Business description
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
Contact
101 Cambridgepark Drive
CambridgeMA02140
USAT: +1 617 945-9626
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
66
Stocks News & Analysis
stocks
Chart of the Week: BHP’s growth story faces a reality check
China’s slowing economy could weigh on BHP’s future growth.
stocks
3 best ASX growth stocks to buy for the long term
Here’s three high-quality growth companies with wide moats.
stocks
The ASX data center stock flying under the radar
While markets chase AI hype, this data centre company offers real data center earnings and a visible growth pipeline.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,021.80 | 28.10 | -0.31% |
| CAC 40 | 8,382.43 | 15.58 | 0.19% |
| DAX 40 | 24,999.53 | 147.50 | -0.59% |
| Dow JONES (US) | 52,658.64 | 150.37 | 0.29% |
| FTSE 100 | 10,515.92 | 13.47 | -0.13% |
| HKSE | 25,157.56 | 476.46 | 1.93% |
| NASDAQ | 26,269.23 | 162.22 | 0.62% |
| Nikkei 225 | 67,044.71 | 1,706.80 | -2.48% |
| NZX 50 Index | 13,608.61 | 26.46 | -0.19% |
| S&P 500 | 7,572.40 | 28.81 | 0.38% |
| S&P/ASX 200 | 8,825.90 | 30.30 | -0.34% |
| SSE Composite Index | 3,923.20 | 32.38 | -0.82% |